用于捕获和分析癌症治疗中免疫相关不良事件(irAEs)的电子健康工具的开发。

IF 2.4 Q2 MATHEMATICAL & COMPUTATIONAL BIOLOGY Cancer Informatics Pub Date : 2023-01-01 DOI:10.1177/11769351231178587
Saeed Moradian, Shive Ghasemi, Babak Boutorabi, Zakieh Sharifian, Fay Dastjerdi, Catriona Buick, Charlotte T Lee, Samantha J Mayo, Plinio P Morita, Doris Howell
{"title":"用于捕获和分析癌症治疗中免疫相关不良事件(irAEs)的电子健康工具的开发。","authors":"Saeed Moradian,&nbsp;Shive Ghasemi,&nbsp;Babak Boutorabi,&nbsp;Zakieh Sharifian,&nbsp;Fay Dastjerdi,&nbsp;Catriona Buick,&nbsp;Charlotte T Lee,&nbsp;Samantha J Mayo,&nbsp;Plinio P Morita,&nbsp;Doris Howell","doi":"10.1177/11769351231178587","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Immunotherapy has revolutionized the treatment of many different types of cancer, but it is associated with a myriad of immune-related adverse events (irAEs). Patient-reported outcome (PRO) measures have been identified as valuable tools for continuously collecting patient-centered data and are frequently used in oncology trials. However, few studies still research an ePRO follow-up approach on patients treated with Immunotherapy, potentially reflecting a lack of support services for this population.</p><p><strong>Methods: </strong>The team co-developed a digital platform (V-Care) using ePROs to create a new follow-up pathway for cancer patients receiving immunotherapy. To operationalize the first 3 phases of the CeHRes roadmap, we employed multiple methods that were integrated throughout the development process, rather than being performed in a linear fashion. The teams employed an agile approach in a dynamic and iterative manner, engaging key stakeholders throughout the process.</p><p><strong>Results: </strong>The development of the application was categorized into 2 phases: \"user interface\" (UI) and \"user experience\" (UX) designs. In the first phase, the pages of the application were segmented into general categories, and feedback from all stakeholders was received and used to modify the application. In phase 2, mock-up pages were developed and sent to the Figma website. Moreover, the Android Package Kit (APK) of the application was installed and tested multiple times on a mobile phone to proactively detect and fix any errors. After resolving some technical issues and adjusting errors on the Android version to improve the user experience, the iOS version of the application was developed.</p><p><strong>Discussion: </strong>By incorporating the latest technological developments, V-Care has enabled cancer patients to have access to more comprehensive and personalized care, allowing them to better manage their condition and be better informed about their health decisions. These advances have also enabled healthcare professionals to be better equipped with the knowledge and tools to provide more effective and efficient care. In addition, the advances in V-Care technology have allowed patients to connect with their healthcare providers more easily, providing a platform to facilitate communication and collaboration. Although usability testing is necessary to evaluate the efficacy and user experience of the app, it can be a significant investment of time and resources.</p><p><strong>Conclusion: </strong>The V-Care platform can be used to investigate the reported symptoms experienced by cancer patients receiving Immune checkpoint inhibitors (ICIs) and to compare them with the results from clinical trials. Furthermore, the project will utilize ePRO tools to collect symptoms from patients and provide insight into whether the reported symptoms are linked to the treatment.</p><p><strong>Clinical relevance: </strong>V-Care provides a secure, easy-to-use interface for patient-clinician communication and data exchange. Its clinical system stores and manages patient data in a secure environment, while its clinical decision support system helps clinicians make decisions that are more informed, efficient, and cost-effective. This system has the potential to improve patient safety and quality of care, while also helping to reduce healthcare costs.</p>","PeriodicalId":35418,"journal":{"name":"Cancer Informatics","volume":"22 ","pages":"11769351231178587"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/23/10.1177_11769351231178587.PMC10259133.pdf","citationCount":"0","resultStr":"{\"title\":\"Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment.\",\"authors\":\"Saeed Moradian,&nbsp;Shive Ghasemi,&nbsp;Babak Boutorabi,&nbsp;Zakieh Sharifian,&nbsp;Fay Dastjerdi,&nbsp;Catriona Buick,&nbsp;Charlotte T Lee,&nbsp;Samantha J Mayo,&nbsp;Plinio P Morita,&nbsp;Doris Howell\",\"doi\":\"10.1177/11769351231178587\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Immunotherapy has revolutionized the treatment of many different types of cancer, but it is associated with a myriad of immune-related adverse events (irAEs). Patient-reported outcome (PRO) measures have been identified as valuable tools for continuously collecting patient-centered data and are frequently used in oncology trials. However, few studies still research an ePRO follow-up approach on patients treated with Immunotherapy, potentially reflecting a lack of support services for this population.</p><p><strong>Methods: </strong>The team co-developed a digital platform (V-Care) using ePROs to create a new follow-up pathway for cancer patients receiving immunotherapy. To operationalize the first 3 phases of the CeHRes roadmap, we employed multiple methods that were integrated throughout the development process, rather than being performed in a linear fashion. The teams employed an agile approach in a dynamic and iterative manner, engaging key stakeholders throughout the process.</p><p><strong>Results: </strong>The development of the application was categorized into 2 phases: \\\"user interface\\\" (UI) and \\\"user experience\\\" (UX) designs. In the first phase, the pages of the application were segmented into general categories, and feedback from all stakeholders was received and used to modify the application. In phase 2, mock-up pages were developed and sent to the Figma website. Moreover, the Android Package Kit (APK) of the application was installed and tested multiple times on a mobile phone to proactively detect and fix any errors. After resolving some technical issues and adjusting errors on the Android version to improve the user experience, the iOS version of the application was developed.</p><p><strong>Discussion: </strong>By incorporating the latest technological developments, V-Care has enabled cancer patients to have access to more comprehensive and personalized care, allowing them to better manage their condition and be better informed about their health decisions. These advances have also enabled healthcare professionals to be better equipped with the knowledge and tools to provide more effective and efficient care. In addition, the advances in V-Care technology have allowed patients to connect with their healthcare providers more easily, providing a platform to facilitate communication and collaboration. Although usability testing is necessary to evaluate the efficacy and user experience of the app, it can be a significant investment of time and resources.</p><p><strong>Conclusion: </strong>The V-Care platform can be used to investigate the reported symptoms experienced by cancer patients receiving Immune checkpoint inhibitors (ICIs) and to compare them with the results from clinical trials. Furthermore, the project will utilize ePRO tools to collect symptoms from patients and provide insight into whether the reported symptoms are linked to the treatment.</p><p><strong>Clinical relevance: </strong>V-Care provides a secure, easy-to-use interface for patient-clinician communication and data exchange. Its clinical system stores and manages patient data in a secure environment, while its clinical decision support system helps clinicians make decisions that are more informed, efficient, and cost-effective. This system has the potential to improve patient safety and quality of care, while also helping to reduce healthcare costs.</p>\",\"PeriodicalId\":35418,\"journal\":{\"name\":\"Cancer Informatics\",\"volume\":\"22 \",\"pages\":\"11769351231178587\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/23/10.1177_11769351231178587.PMC10259133.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Informatics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11769351231178587\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATHEMATICAL & COMPUTATIONAL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11769351231178587","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

免疫疗法已经彻底改变了许多不同类型癌症的治疗,但它与无数的免疫相关不良事件(irAEs)有关。患者报告结果(PRO)测量已被确定为持续收集以患者为中心的数据的有价值的工具,并经常用于肿瘤试验。然而,很少有研究对接受免疫治疗的患者进行ePRO随访,这可能反映了对这一人群缺乏支持服务。方法:该团队利用ePROs共同开发了一个数字平台(V-Care),为接受免疫治疗的癌症患者创造了新的随访途径。为了实现CeHRes路线图的前3个阶段,我们在整个开发过程中集成了多种方法,而不是以线性方式执行。团队以动态和迭代的方式采用敏捷方法,在整个过程中吸引关键涉众。结果:应用程序的开发分为两个阶段:“用户界面”(UI)和“用户体验”(UX)设计。在第一阶段,将应用程序的页面划分为一般类别,并接收来自所有涉众的反馈,并使用这些反馈来修改应用程序。在第二阶段,开发了模型页面并将其发送到Figma网站。此外,应用程序的Android Package Kit (APK)在手机上进行了多次安装和测试,主动发现并修复任何错误。在解决了Android版本的一些技术问题并调整错误以改善用户体验后,开发了iOS版本的应用程序。讨论:通过结合最新的技术发展,V-Care使癌症患者能够获得更全面和个性化的护理,使他们能够更好地管理自己的病情,并更好地了解自己的健康决定。这些进步还使医疗保健专业人员能够更好地配备知识和工具,以提供更有效和高效的护理。此外,V-Care技术的进步使患者能够更轻松地与医疗保健提供者联系,提供了一个促进沟通和协作的平台。尽管可用性测试对于评估应用的有效性和用户体验是必要的,但它可能需要大量的时间和资源投入。结论:V-Care平台可用于调查接受免疫检查点抑制剂(ICIs)的癌症患者所报告的症状,并将其与临床试验结果进行比较。此外,该项目将利用ePRO工具收集患者的症状,并深入了解所报告的症状是否与治疗有关。临床相关性:V-Care为患者与临床医生的沟通和数据交换提供了一个安全、易于使用的界面。其临床系统在安全的环境中存储和管理患者数据,而其临床决策支持系统帮助临床医生做出更明智、更有效和更具成本效益的决策。该系统具有提高患者安全和护理质量的潜力,同时也有助于降低医疗成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment.

Introduction: Immunotherapy has revolutionized the treatment of many different types of cancer, but it is associated with a myriad of immune-related adverse events (irAEs). Patient-reported outcome (PRO) measures have been identified as valuable tools for continuously collecting patient-centered data and are frequently used in oncology trials. However, few studies still research an ePRO follow-up approach on patients treated with Immunotherapy, potentially reflecting a lack of support services for this population.

Methods: The team co-developed a digital platform (V-Care) using ePROs to create a new follow-up pathway for cancer patients receiving immunotherapy. To operationalize the first 3 phases of the CeHRes roadmap, we employed multiple methods that were integrated throughout the development process, rather than being performed in a linear fashion. The teams employed an agile approach in a dynamic and iterative manner, engaging key stakeholders throughout the process.

Results: The development of the application was categorized into 2 phases: "user interface" (UI) and "user experience" (UX) designs. In the first phase, the pages of the application were segmented into general categories, and feedback from all stakeholders was received and used to modify the application. In phase 2, mock-up pages were developed and sent to the Figma website. Moreover, the Android Package Kit (APK) of the application was installed and tested multiple times on a mobile phone to proactively detect and fix any errors. After resolving some technical issues and adjusting errors on the Android version to improve the user experience, the iOS version of the application was developed.

Discussion: By incorporating the latest technological developments, V-Care has enabled cancer patients to have access to more comprehensive and personalized care, allowing them to better manage their condition and be better informed about their health decisions. These advances have also enabled healthcare professionals to be better equipped with the knowledge and tools to provide more effective and efficient care. In addition, the advances in V-Care technology have allowed patients to connect with their healthcare providers more easily, providing a platform to facilitate communication and collaboration. Although usability testing is necessary to evaluate the efficacy and user experience of the app, it can be a significant investment of time and resources.

Conclusion: The V-Care platform can be used to investigate the reported symptoms experienced by cancer patients receiving Immune checkpoint inhibitors (ICIs) and to compare them with the results from clinical trials. Furthermore, the project will utilize ePRO tools to collect symptoms from patients and provide insight into whether the reported symptoms are linked to the treatment.

Clinical relevance: V-Care provides a secure, easy-to-use interface for patient-clinician communication and data exchange. Its clinical system stores and manages patient data in a secure environment, while its clinical decision support system helps clinicians make decisions that are more informed, efficient, and cost-effective. This system has the potential to improve patient safety and quality of care, while also helping to reduce healthcare costs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Informatics
Cancer Informatics Medicine-Oncology
CiteScore
3.00
自引率
5.00%
发文量
30
审稿时长
8 weeks
期刊介绍: The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.
期刊最新文献
Detecting the Tumor Prognostic Factors From the YTH Domain Family Through Integrative Pan-Cancer Analysis. Unveiling Recurrence Patterns: Analyzing Predictive Risk Factors for Breast Cancer Recurrence after Surgery. Understanding the Biological Basis of Polygenic Risk Scores and Disparities in Prostate Cancer: A Comprehensive Genomic Analysis. Machine Learning for Dynamic Prognostication of Patients With Hepatocellular Carcinoma Using Time-Series Data: Survival Path Versus Dynamic-DeepHit HCC Model. Advancements and Challenges in the Image-Based Diagnosis of Lung and Colon Cancer: A Comprehensive Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1